An RFD is submitted to the Office of Combination Products to determine the classification of a product (drug, device, biologic, or combination) and assign the lead FDA Center based on primary mode of action. Sponsors file one when a product's classification or lead center is unclear or disputed. FDA must issue a designation letter within 60 days, or the sponsor's own recommendation becomes the designation. A less formal Pre-RFD gives preliminary, non-binding feedback, and the process is set out in 21 CFR Part 3.

Why it matters

Often used early in development for novel combination products to remove ambiguity about the regulatory pathway and applicable cGMP requirements.

Common pitfalls

•A common pitfall is submitting an RFD too late in the development process, which can lead to costly delays if the product is misclassified.
•Failing to provide a clear and well-supported primary mode of action in the RFD can result in an unfavorable or delayed designation.
•Assuming an RFD is only for novel combination products is a mistake, as it can also be beneficial for products with unclear classifications.
•Not thoroughly understanding the distinctions between drug, device, and biologic classifications can lead to an inaccurate RFD submission.

Sources

FDA - Medical Devices · FDA
European Commission - Medical Devices · European Commission
IMDRF Documents · IMDRF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.